MedTrace Logo

GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma

NCT07673692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1372

Last updated 2026-06-29

No results posted yet for this study

Summary

The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-GBM can help detect a specific molecular type of brain tumour called IDH wildtype glioblastoma using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA).

The main questions it aims to answer are:

* How accurately can GliomaAI-GBM identify IDH wildtype glioblastoma from MRI scans?
* How well does the system perform across data from different hospitals and patient groups?

Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database.

Participants will not be asked to do anything, as this study only uses previously collected imaging data.

Conditions

  • Glioma
  • Glioma (Diagnosis)
  • Glioblastom WHO Grade 4
  • IDH Wildtype Glioblastoma

Interventions

DEVICE

GliomaAI-GBM

Software as Medical Device (SaMD) for predicting histological glioblastoma

Sponsors & Collaborators

  • Deep Learning Institute of Radiological Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-14
Primary Completion
2021-03-09
Completion
2021-07-16
FDA Device
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07673692 on ClinicalTrials.gov